论文部分内容阅读
目的探讨脑梗死早期患者应用大剂量尿激酶溶栓进行治疗的临床疗效。方法 78例急性脑梗死患者分为溶栓组和对照组,各39例。溶栓组采用尿激酶和低分子肝素治疗;对照组采用低分子肝素治疗。观察两组治疗效果。结果溶栓组疗效优于对照组(P<0.05);溶栓治疗组患者治疗2、4、24 h后与治疗前各指标差异有统计学意义(P<0.05);在治疗48 h时,PT、TT、Fg与治疗前比较差异有统计学意义(P<0.05),APTT与治疗前比较差异无统计学意义(P>0.05)。结论在正确把握溶栓治疗的时间窗、适应证时,应用大剂量尿激酶对急性脑梗死的早期患者进行静脉溶栓治疗安全有效。
Objective To investigate the clinical efficacy of high-dose urokinase thrombolysis in patients with early cerebral infarction. Methods 78 patients with acute cerebral infarction were divided into thrombolytic group and control group, 39 cases each. Thrombolysis group treated with urokinase and low molecular weight heparin; control group treated with low molecular weight heparin. Observation of two groups treatment effect. Results The curative effect of thrombolysis group was better than that of control group (P <0.05). There was significant difference between the two groups (P <0.05) PT, TT, Fg were significantly different from those before treatment (P <0.05). There was no significant difference in APTT between before and after treatment (P> 0.05). Conclusion In the correct grasp of the thrombolytic time window, indications, the application of high-dose urokinase in patients with acute cerebral infarction in patients with intravenous thrombolysis safe and effective.